Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) research hub
5 indexed studies · 3 currently recruiting
- recruitingPHASE4
Fibrosis Lessens After Metabolic Surgery
This study looks at how well weight-loss surgery compares to new medicines for treating liver disease. It focuses on a condition called MASH, which is linked to being overweight and can cause liver damage.
United States · Brazil · Canada - recruitingPHASE3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study looks at a new medicine called survodutide for adults with a liver condition called MASH and moderate to advanced liver damage. It aims to see if the medicine can improve liver health and how safe it is.
United States · Argentina · Australia - authorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)
This study is testing a new medicine, Efimosfermin alfa, for people with a type of liver disease called MASH. We want to see if it can improve liver scarring and damage. One group will get the medicine, and others will get a dummy treatment.
Belgium · Greece - not yet recruitingNA
Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
This study looks at how gut bacteria in people with a common liver condition (MASLD) produce certain chemicals. We want to see if these chemicals cause the liver problems, which could lead to new treatments. We'll collect stool, blood, and urine samples.
France - recruitingPhase I/II
A Phase I/II study of TGM-312-SC01 in healthy participants and adults with metabolic dysfunction-associated steatohepatitis
This study is testing a new medicine, TGM-312-SC01, for a liver condition called MASH. Researchers want to see if it's safe for healthy people and those with MASH, and if it shows early signs of helping people with MASH.
United Kingdom · England